• 进行合作扩大亚洲、海外、英国及英国，即将1HLX13在癌肿免疫细胞联席冶疗方向的国内可及性

不同服务协议条款内容，复宏汉霖将承接HLX13的新企业产品开发、产量及其业务化供货，并从成交中赢得3.02亿澳元的潜在性的薪水，但其中350万澳元为成交购车首支付。用作亚洲仿制药与微海洋生物制品接近药前沿技术的老板者，山德士一直以来都以“让绿色随手可及”为责任担当，要借助约1,300款企业产品连续劳有所得亚洲9亿人群。本次复宏汉霖一同山德士，将彻底的借助其较为成熟的亚洲系统与微海洋生物制品接近药业务化优势，加速度HLX13在亚洲流行的微海洋生物制品药销售市场的可及性。

复宏汉霖实施程序高管、总裁实施程序官

朱俊硕士生写出

复宏汉霖首席霸道总裁商务旅行发展趋势官兼高等 副经理裁

曹平男式说道

HLX13是复宏汉霖自研微生物这样药管网的重要性组建，其原研药伊匹木单抗（Yervoy^®）用作世界排名首批CTLA-4抑制作用剂，已在很多个一个国家和东南部将建，应用症其中包括连合纳武利尤单抗使用一样素瘤、肝组织细胞癌等一系例应用症。复宏汉霖已勾勒打了个体化世界排名研发培训、药政办理及临床试验開發运营推广平台网站，并设计规划了贴合世界排名药品监督操作规范要求的制造和水平操作操作标准，成就驱动4款厂品在国外投资市扬将建开卖。厂家将全面的有序推进HLX13的世界排名開發阶段，专注于于共话加盟盟友为世界排名我们打造更加优质化量操作可经济负担的治療设计。

 Henlius Enters into License Agreement with Sandoz for Proposed Ipilimumab Biosimilar

• Partnership covers North America, Europe, Japan, and Australia to accelerate global access of HLX13 in immuno-oncology combinations

• Henlius to receive $31 million upfront, and up to $270 million in milestones

On April 29, 2025, Shanghai Henlius Biotech, Inc. (2696.HK) announced a licensing agreement with Sandoz (SIX: SDZ; OTCQX: SDZNY), the global leader in generic and biosimilar medicines, granting exclusive commercialization rights for its self-developed ipilimumab biosimilar HLX13 in the United States, 42 European countries and regions, Japan, Canada, and Australia.

Under the agreement, Henlius will be responsible for development, manufacturing and commercial supply of HLX13, and is eligible to receive up to a total of $301 million, including a $31 million upfront and additional milestone payments. As the global leader in generic and biosimilar medicines, Sandoz is committed to its purpose of “pioneering access for patients” and has benefited over 900 million patients worldwide with approximately 1,300 products. This collaboration will leverage Sandoz’s established global network and commercialization expertise to accelerate the accessibility of HLX13 in mainstream biopharma markets.

“At Henlius, we remain deeply committed to delivering high-quality biologics to patients around the world,” said Dr. Jason Zhu, Executive Director and Chief Executive Officer of Henlius. “Our collaboration with Sandoz marks another important step toward enhancing the global accessibility of our therapies. We believe that putting patients at the core of our globalization strategy is key to fulfilling our vision of ‘Developed in China, Access for the World.’”

“We’re excited to join forces with Sandoz,” said Ping Cao, Chief Business Officer and Senior Vice President of Henlius. “By combining Henlius’ proven strengths in biologics R&D and manufacturing with extensive global reach and commercialization expertise of Sandoz, we aim to accelerate the worldwide expansion of HLX13 and bring advanced treatment options to more patients across key markets.”

HLX13 is a key component of Henlius’ self-developed biosimilar pipeline. Its reference product, Yervoy^®, the world’s first CTLA-4 inhibitor, has been approved in various countries and regions in combination with nivolumab for the treatment of melanoma and hepatocellular carcinoma, among other indications. Henlius has established an integrated global platform for R&D, regulatory registration, and clinical operations, backed by a manufacturing and quality management system that meets global regulatory standards. The company has successfully launched four products in markets beyond China. Henlius is committed to advancing the global development of HLX13 and working with partners to provide more high-quality, affordable treatment options for patients worldwide.

*Yervoy^® is a registered trademark of Bristol-Myers Squibb (US)